Member Info for HotblackDesiato

Timbo - sorry, yes, you're quite right, it's 20%.

Ohnonotagain - depending on your situation you might want to risk transferring half now while it's still fairly quiet then do the other half. Depending on how many shares you have it might be worth a smallish hit now compared to the 40% you might pay in CGT.

Metalbasher - sage words.

All of my SAR tickets are safe from the govt.

After much cogitation over the last few days I've sold other shares in my ISA at a bit of a loss (always painful) to add to my SAR holding. The science is on a firm footing so I'm confident my investment is safe....ish.

Sorry - typo - Mafuta.

Mufata - not necessarily scaremongering as such (though I understand the point of view), maybe more a case of understanding all options available?

I think I've found the answer I'm looking for in the RNS from last year - https://www.lse.co.uk/rns/SAR/primarybidcom-offer-xuref68g7944s5q.html

If only I'd looked there first!

Kernowlad - thanks for the quick reply.

Would someone be good enough to clarify what the process is if SAR need to issue more shares?

If they first offer shareholders discounted shares based on their current holding and are over-subscribed, is it first come, first served or do shareholders then enter some sort of lottery to see if they get the shares they wanted to buy?

Also, what sort of timescale is usually involved between announcement and you getting your shares?

Thanks!

I have no idea how recent developments have changed things but RMM kindly posted their thoughts on this back in early Jan:

"...….There are conflicting sizes for the Parkinsons therapeutics global market size (somewhere between £2.8bn and £4.6bn). I’ve gone with the lower estimate just to be prudent. Roche have achieved annual sales of around £278m with Madopar which equates to a 10% share. If one of our molecules was to perform similarly then the lifetime value would be over £2bn. Given the stage we are at a heavily discounted (90%) value would put 7p on the current SP. Get it into P1, with good data and this could easily rise to 21p. At the higher end of the global market estimate we’d be looking at 11.5 and 34p respectively. However, this tends to pale into insignificance when you look at the Covid therapeutics market (excluding vaccines) which was estimated at £13.2bn in 2020. Given the rate of mutation this could easily double in 2021. If TYK2 was to prove effective and gain a 5% share we’d be looking at sales in the region of £1.3bn pa. However, I think a lower P/E is required as vaccines improve and the industry gets on top of the virus. On this basis discounted value today would be 6p on the SP. Get it to P1 and we’re looking at 19p on the SP beyond that it gets serious. Combined value of TYK2 - my previous estimate was around 20p for where we are currently, add on Parkinsons and Covid and we have a SP in the region of 33p today rising to 60p. Then add in FLT3 and that probably adds another 12p minimum. 737 could add another 15p once it gets kick started in anogenital. Then there’s the SKIL platform which I understand to be worth 6p. Total value today in the region of 93p..."

Now if only that were legally binding!

Bluedreamer - the thing is, over the years I've spent as much on my hifi as I did buying my flat. Dang, it sounds good! So without wishing to sound greedy, anything north of 79p would buy me a well-appointed home with plenty money left over for a larger guitar collection etc. and maybe a spot of altruism too (I'm not a complete git).

Potnak - To be honest I'll take whatever we're given. I live in a smallish flat and my dream is to afford a house where I can play music loud enough to peel the wallpaper (I'm currently quiet as a mouse as I don't want to be a bad neighbour).

Potnak - yeah, my thinking too. If we look like getting anywhere close to 30p a share / £1bn valuation then I suspect big pharma will wade in. The question is, will Sareum be happy to sell out having created a £1bn company with effective treatments or hold out for £1+ per share?

Casper - Oh I'm sure they'll be back but we'll just humour them like the petulant children they are, "Yes, yes, dear. If you're nice and quiet while the grown-ups talk you'll get ice cream later on".

Hopefully with the positive outlook for SAR we can say a final farewell to our trolls (paid or unpaid).

Yes, we're still some way from complete validation but it's clear that management are doing something right.

There will be a nanosecond's silence for Charlie (both the original and their clone) at close of trade today. Trousers to remain at halfmast for the duration. It's what they would have wanted.

Join Sareum Holdings Plc's investor presentation on 28th April at 11:00, for all the company insights

Eeeek! Looks like I might be too late to get a cheap top-up! Maybe I already have enough shares to make me rich...time will tell.

Yup, it might be a sleepless night as I decide to sell other shares in my ISA and stock up on SAR tomorrow.

Hmmm, the only certainty in life is death - taxes can be avoided.

Bluedreamer - qu’est-ce que c’est? Fa fa fa etc.

(I never liked the song when it came out but don't mind it now!)

Thanks Thoth.

So to answer Damion's concern, "In the absence of adverse effects to define the MTD, the high dose of a general regulatory toxicology study can be selected by the limit dose, saturation of exposure, or maximum feasible dose."